The rise of GLP-1 drugs like Ozempic are changing consumer food waste patterns both at home and in restaurant settings.

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

Dr Harriet Treacy, co-founder of Beyondbmi, spoke with EVOKE to explain that obesity is a disease that requires medical treatment, whereas many people are simply availing of the drugs to lose a few ...

A new University of Michigan study shows that a strong majority of older Americans want health insurance — including Medicare — to cover weight loss medica ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

While experts welcomed Mounjaro's launch, they stressed the importance of responsible prescribing to prevent misuse of the drug used for the treatment of type 2 diabetes and obesity.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a ...